HIV‐Associated Pulmonary Arterial Hypertension in Resource‐Limited Settings: A “Forgotten” Diagnosis, a Great Imitator, and a Multi‐Hit Pulmonary Vasculopathy Authors: Emmanuel Eroume A Egom, Mfopa Adamou, Ibrahima Djouldé, Njimona Ibrahim, Mountchissi Célestin, Lum Abenwi Ambe, Medou Mba Fabrice, Moustapha, René Kamgang Published: 2026 ABSTRACT ABSTRACTHIV‐associated pulmonary arterial hypertension (HIV‐PAH) remains one of the most consequential cardiopulmonary complications in people living with HIV (PLWH), persisting despite expanded antiretroviral therapy (ART) coverage. Although contemporary hemodynamic criteria define pulmonary hypertension (PH) as mean pulmonary arterial pressure (mPAP) > 20 mmHg and pulmonary arterial hypertension (PAH) as pre‐capillary physiology confirmed by right heart catheterization (mPAP > 20 mmHg, pulmonary arterial wedge pressure ≤ 15 mmHg, pulmonary vascular resistance > 2 Wood units), global epidemiologic certainty remains uneven. In high‐income settings, prospective screening paradigms incorporating catheter confirmation estimate HIV‐PAH prevalence at approximately 0.5%, exemplified by the multicenter French study reporting 0.46%. In contrast, in sub‐Saharan Africa—home to more than 26 million PLWH—the population prevalence of catheter‐confirmed HIV‐PAH remains undefined, with echocardiography‐based studies in symptomatic cohorts reporting substantially higher rates of elevated pulmonary pressures. Mechanistically, HIV‐PAH is best conceptualized as a multi‐hit pulmonary vasculopathy driven by viral proteins (Tat, Nef, gp120), chronic immune activation, endothelial dysfunction, oxidative stress, dysregulated endothelin signaling, and growth‐factor pathways, with amplification by endemic co‐factors and host susceptibility. Clinically, HIV‐PAH is a “clinically nonspecific phenotype”, frequently obscured by tuberculosis‐related lung disease, anemia, left heart disease, and other causes of dyspnea in resource‐limited settings. Early recognition is critical because prognosis depends on preservation of right ventricular function. A practical, resource‐appropriate strategy is required: heightened clinical suspicion, echocardiography‐anchored detection, systematic exclusion of alternative PH etiologies, rational biomarker use, and referral pathways to right heart catheterization where feasible. ART optimization is necessary but insufficient; PAH‐targeted therapies can improve functional and hemodynamic outcomes, though HIV‐specific randomized evidence remains limited. Implementation science and mechanism‐informed research in endemic regions are urgently needed to close the diagnostic and therapeutic gap. Abbreviations 6‐min walk distance Antiretroviral therapy Chronic thromboembolic pulmonary hypertension Cytochrome P450 Direct oral anticoagulant Endothelin receptor antagonist HIV‐associated pulmonary arterial hypertension International normalized ratio Pulmonary arterial hypertension Phosphodiesterase type 5 Pulmonary hypertension People living with HIV Right ventricle Soluble guanylate cyclase World Health Organization Context: Why HIV‐PAH Remains “Forgotten” Global HIV epidemiology has shifted decisively from an acute, frequently fatal infection to a chronic condition shaped by long‐term survival and multimorbidity. The World Health Organization reports that in 2024 an estimated 1.3 million people acquired HIV and ~630,000 people died from HIV‐related causes, with substantial regional heterogeneity in prevention, diagnosis, treatment coverage, and viral suppression [1]. Concordant estimates are provided in the UNAIDS “Global HIV & AIDS statistics” fact sheet and its accompanying 2025 PDF summary [2, 3]. As the global HIV population ages, the clinical center of gravity increasingly includes non‐infectious cardiopulmonary conditions, many of which present insidiously and compete with (or mimic) infectious disease syndromes. Within this landscape, HIV‐associated pulmonary arterial hypertension (HIV‐PAH) remains particularly consequential because it is a progressive pulmonary vasculopathy that threatens survival through right ventricular failure and because its earliest symptoms are often indistinguishable from far more common conditions. Contemporary reviews emphasize that HIV‐PAH continues to occur in the antiretroviral therapy era and carries substantial morbidity and mortality when not recognized and treated [4]. Earlier cohort data underscore the prognostic severity of HIV‐PAH and the centrality of cardiopulmonary limitation and right‐heart dysfunction to outcomes [5]. In resource‐limited settings, the problem is magnified by clinical overlap. Fatigue, dyspnea, cough, syncope, edema, and chest discomfort—typical of pulmonary hypertension—also occur in tuberculosis, post‐tuberculosis lung disease, recurrent pneumonia, bronchiectasis, anemia, and heart failure, all of which are prevalent among people living with HIV. Post‐tuberculosis lung disease has been highlighted as a major, under‐recognized driver of chronic respiratory morbidity in high‐burden regions, providing a frequent alternative explanation for exertional dyspnea and hypoxia [6, 7, 8]. In parallel, heart failure and structural heart disease are increasingly documented in people living with HIV, including in sub‐Saharan Africa, further complicating symptom attribution and echocardiographic interpretation [9, 10, 11]. The predictable consequence is delayed recognition, misclassification, and missed opportunity to intervene before right ventricular decompensation becomes irreversible—an imperative that makes definitions and phenotyping more than methodological details. Definitions That Matter: Contemporary Hemodynamic Criteria and the Logic of Classification Modern definitions of pulmonary hypertension (PH) reflect a shift toward earlier hemodynamic recognition and greater precision in distinguishing pulmonary vascular disease from secondary elevations in pulmonary pressure. The 2022 ESC/ERS Guidelines define pulmonary hypertension as a resting mean pulmonary arterial pressure (mPAP) > 20 mmHg, measured by right heart catheterization. Pre‐capillary PH is defined by the combined presence of mPAP > 20 mmHg, pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 2 Wood units; pulmonary arterial hypertension (PAH) is then reserved for patients with pre‐capillary hemodynamics whose clinical context aligns with World Health Organization group 1 etiologies, explicitly including HIV infection [12]. These thresholds are not semantic refinements: they shape screening sensitivity, determine how “borderline” hemodynamics are interpreted, and set the basis for comparability across studies and registries. Classification is especially important in HIV because elevated pulmonary pressures in people living with HIV frequently reflect mixed or alternative mechanisms rather than isolated group 1 PAH. The contemporary clinical classification framework recognizes that PH spans: group 1 PAH (including HIV‐PAH and schistosomiasis‐associated PAH), group 2 PH due to left heart disease, group 3 PH due to chronic lung disease and/or hypoxia, group 4 chronic thromboembolic pulmonary hypertension (CTEPH), and group 5 PH associated with multifactorial systemic or hematologic disorders [13]. In practice, this means that an echocardiogram suggesting elevated pulmonary pressures is only a starting point; the decisive step is determining whether the physiology is truly pre‐capillary and, if so, whether the clinical phenotype fits group 1 PAH or another category requiring fundamentally different management. Key phenotype‐based distinctions that separate HIV‐PAH from other common causes of pulmonary hypertension in PLWH are summarized in Table 1. Table 1Phenotyping pulmonary hypertension in people living with HIV: practical distinctions that change management.PH category (WHO group)Common causes relevant to PLWHClinical cluesKey tests (minimum set)Implications for therapyGroup 1: PAH (including HIV‑PAH; schistosomiasis‑PAH)Progressive pulmonary arteriopathy; may coexist with schistosomiasis in endemic regionsExertional dyspnea/syncope out of proportion to parenchymal lung findings; RV enlargement/dysfunction on echocardiographyEchocardiography plus exclusion of left heart disease and major lung disease; confirm with RHC (mPAP > 20, PAWP ≤ 15, PVR > 2)PAH‑targeted therapy appropriate after confirmation and interaction review; RV‑focused follow‑upGroup 2: PH due to left heart diseaseHIV‑associated cardiomyopathy, hypertension, ischemic disease, valvular diseaseOrthopnea or congestion symptoms; LV systolic/diastolic dysfunction or significant valve diseaseEchocardiography (LV function/valves); natriuretic peptides; consider RHC if uncertainty persistsTreat left heart disease; avoid PAH drugs unless pre‑capillary PAH confirmedGroup 3: PH due to lung disease/hypoxiaPost‑TB lung disease, COPD, bronchiectasis, chronic hypoxiaCough/sputum, prior TB, hypoxemia; parenchymal abnormalities on chest imagingPulse oximetry; chest radiograph; spirometry when available; consider CT if accessibleOptimize lung disease; oxygen when indicated; PAH therapy generally not indicatedGroup 4: CTEPHPrior venous thromboembolism; underrecognized where imaging is limitedExertional limitation with thrombotic risk factors; persistent dyspnea after acute PEV/Q scan preferred; CT pulmonary angiography where availableAnticoagulation and referral for operability/intervention; do not misclassify as PAHGroup 5: PH with multifactorial mechanismsHemoglobinopathies (e.g., sickle cell), systemic disordersAnemia/hemolysis, systemic disease features; variable phenotypeCBC; hemoglobin electrophoresis where relevant; RHC if treatment decisions hinge on phenotypeTreat underlying condition; consider specialist referral for mixed mechanismsAbbreviations: CBC, complete blood count; COPD, chronic obstructive pulmonary disease; CT, computed tomography; CTEPH, chronic thromboembolic pulmonary hypertension; LV, left ventricle; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP, pulmonary arterial wedge pressure; PE, pulmonary embolism; PH, pulmonary hypertension; PLWH, people living with HIV; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricle; TB, tuberculosis; V/Q, ventilation–perfusion.John Wiley & Sons, Ltd. Phenotyping pulmonary hypertension in people living with HIV: practical distinctions that change management. Abbreviations: CBC, complete blood count; COPD, chronic obstructive pulmonary disease; CT, computed tomography; CTEPH, chronic thromboembolic pulmonary hypertension; LV, left ventricle; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP, pulmonary arterial wedge pressure; PE, pulmonary embolism; PH, pulmonary hypertension; PLWH, people living with HIV; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricle; TB, tuberculosis; V/Q, ventilation–perfusion. This point is especially salient in African settings, where post‐tuberculosis lung disease, chronic respiratory infection, anemia, left‐heart disease, and endemic co‐exposures can dominate the differential diagnosis. Echocardiography‐based African studies report substantial proportions of HIV‐infected patients meeting study‐specific criteria for “pulmonary hypertension,” but heterogeneous thresholds and limited catheter confirmation underscore that detection alone does not establish HIV‐PAH [14]. The dual purpose of the modern definition is therefore clear: it standardizes hemodynamic diagnosis while enforcing a disciplined, phenotype‐driven approach that is essential for accurate epidemiology, safe therapy selection, and credible clinical research. This classification logic naturally sets the stage for the sections that follow—first, the epidemiologic uncertainties created by uneven access to catheter confirmation, and then the clinical phenotype in which early recognition is the critical determinant of right ventricular preservation. Epidemiology: What We Know, What We Infer, and What We Still Do Not Know Once contemporary hemodynamic definitions are accepted, the central epidemiologic question is how often HIV‐associated pulmonary arterial hypertension (HIV‐PAH) occurs and which populations are most affected. The answer differs sharply by setting—not only because biology and co‐exposures vary, but because ascertainment infrastructure (screening, phenotyping, and catheter confirmation) is unevenly distributed. High‐Income Settings: Reproducible Prevalence, Persistent Ascertainment Bias The most frequently cited prevalence estimate for HIV‐PAH remains approximately one half of one percent, anchored by prospective screening studies that incorporated confirmatory right heart catheterization. In a multicenter French cohort, Sitbon and colleagues screened 7,648 consecutive adults with HIV and identified HIV‐PAH using a predefined diagnostic algorithm culminating in catheter confirmation, reporting a prevalence of 0.46% [15]. This estimate should be interpreted against the rarity of PAH in the general population; in the French registry, the estimated annual incidence of PAH was 2.4 cases per million adults per year [14]. Yet even in well‐resourced environments, prevalence estimates are shaped by structural and methodological biases. Screening cascades often begin with symptoms (e.g., unexplained dyspnea), potentially missing milder or earlier disease; echocardiographic thresholds that trigger catheterization vary; and not all patients with elevated estimated pulmonary pressures undergo invasive confirmation. In parallel, as people living with HIV age, competing causes of pulmonary hypertension (left heart disease, chronic lung disease, thromboembolic disease) become more common, increasing the risk that “HIV‐PH” is misclassified as HIV‐PAH unless phenotyping is rigorous [13]. Table 2 summarizes key epidemiologic studies and systematic reviews that inform estimates of HIV‐associated pulmonary arterial hypertension and HIV‐associated pulmonary hypertension worldwide, including early Swiss clinical observations [16, 17], ART‐era Swiss outcome data [18], French catheter‐confirmed screening data [15], Spanish echocardiographic risk‐factor data [19], African echocardiography‐based estimates [14], global systematic review evidence [20], and PAPUCO data from sub‐Saharan Africa [21]. The table separates catheter‐confirmed PAH from echocardiography‐defined PH because these approaches estimate different clinical entities: invasive cohorts approximate true pre‐capillary Group 1 HIV‐PAH, whereas echocardiographic cohorts detect a broader PH signal that may include left heart disease, chronic lung disease, post‐tuberculosis sequelae, hypoxic pulmonary vascular disease, and thromboembolic disease [12, 13]. This distinction is particularly important in resource‐limited settings, where echocardiography‐defined PH identifies a clinically important high‐risk cardiopulmonary phenotype but cannot, without invasive phenotyping, define the population prevalence of catheter‐confirmed HIV‐PAH [14, 21]. Table 2Key epidemiologic studies informing HIV‐associated PAH/PH estimates worldwide.StudySetting/populationDiagnostic definitionKey findingInterpretationSpeich et al., [16]Switzerland; early HIV‐era clinical cohort.Historical primary pulmonary hypertension definition.Six cases among approximately 1,200 HIV‐infected individuals, suggesting an early prevalence signal near 0.5%.Historical pre‐modern ART estimate; definitions preceded current hemodynamic criteria.Opravil et al., [17]Swiss HIV Cohort case‐control experience.HIV‐associated primary pulmonary hypertension.Women and injecting drug exposure predominated; median CD4 count was 83 cells/microliter.Important early risk‐phenotype study, not a population prevalence estimate.Zuber et al., [18]Swiss HIV Cohort.HIV‐related PAH clinical cohort.ART was associated with improved hemodynamics and survival.Observational treatment‐era evidence.Sitbon et al., [15]France; 7,648 consecutive adults with HIV.Screening algorithm with right heart catheterization confirmation.HIV‐PAH prevalence 0.46%.Benchmark contemporary catheter‐confirmed prevalence estimate.Quezada et al., [19]Spain; HIV clinic cohort.Doppler echocardiography; elevated RV pressure threshold.Echocardiography‐defined PH/PAH was substantially higher than catheter‐confirmed estimates; female sex, detectable HIV RNA, and HCV were associated with elevated pressures.Useful risk‐factor signal; echo‐only design limits PAH specificity.Bigna et al., [14]Africa; systematic review/meta‐analysis.Echocardiography‐based PH, commonly PASP > = 35 mmHg.Pooled prevalence 14% among 664 symptomatic African adults with HIV.Demonstrates high PH signal in selected symptomatic cohorts; not equivalent to HIV‐PAH prevalence.Bigna et al., [20]Global systematic review/meta‐analysis; 25 studies, 42,642 participants.Echocardiography or right heart catheterization.Adult echocardiography‐defined PH prevalence 8.3%; only one RHC‐based adult study reported 0.5%.Shows global heterogeneity and the scarcity of RHC‐confirmed data.Thienemann et al., [21], PAPUCOSub‐Saharan Africa; HIV‐positive PH cohort within PAPUCO.Echocardiography‐based PH with WHO‐group clinical classification.Among HIV‐positive PH patients, 36% were classified as Group 1 PAH, 36% as Group 2 PH‐LHD, and 19% as Group 3 PH‐LD; Group 3 PH‐LD was attributed to previous TB in all HIV‐positive cases.Strong evidence that PH in African PLWH is etiologically heterogeneous and frequently confounded by TB and left heart disease. Note: This table separates catheter‐confirmed PAH from echocardiography‐defined PH because these approaches answer different questions. Invasive cohorts estimate true pre‐capillary Group 1 disease, whereas echocardiographic cohorts capture a broader PH signal that may include left heart disease, chronic lung disease, post‐tuberculosis sequelae, and thromboembolic disease.Abbreviations: ART, antiretroviral therapy; HCV, hepatitis C virus; HIV‐PAH, HIV‐associated pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PASP, pulmonary artery systolic pressure; PH, pulmonary hypertension; PH‐LD, pulmonary hypertension due to lung disease and/or hypoxia; PH‐LHD, pulmonary hypertension due to left heart disease; PLWH, people living with HIV; RHC, right heart catheterization; RV, right ventricle; TB, tuberculosis; WHO, World Health Organization.John Wiley & Sons, Ltd. Key epidemiologic studies informing HIV‐associated PAH/PH estimates worldwide. Note: This table separates catheter‐confirmed PAH from echocardiography‐defined PH because these approaches answer different questions. Invasive cohorts estimate true pre‐capillary Group 1 disease, whereas echocardiographic cohorts capture a broader PH signal that may include left heart disease, chronic lung disease, post‐tuberculosis sequelae, and thromboembolic disease. Abbreviations: ART, antiretroviral therapy; HCV, hepatitis C virus; HIV‐PAH, HIV‐associated pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PASP, pulmonary artery systolic pressure; PH, pulmonary hypertension; PH‐LD, pulmonary hypertension due to lung disease and/or hypoxia; PH‐LHD, pulmonary hypertension due to left heart disease; PLWH, people living with HIV; RHC, right heart catheterization; RV, right ventricle; TB, tuberculosis; WHO, World Health Organization. Risk‐factor interpretation remains heterogeneous because available studies have used different outcome definitions, ranging from catheter‐confirmed HIV‐PAH to echocardiography‐defined PH. In early Swiss case‐control data, women and people with injecting drug exposure were over‐represented among HIV‐associated primary pulmonary hypertension cases, and the median CD4 count was 83 cells/µL [17]. In a Spanish echocardiographic HIV cohort, female sex, detectable HIV RNA, and chronic hepatitis C virus infection were independently associated with elevated pulmonary pressures [19]. A later global systematic review similarly identified female sex, detectable HIV RNA, hepatitis C virus infection, increasing age, NT‐proBNP, smoking, and ART exposure duration as risk variables reported across studies [14]. Incident PH data from the Veterans Aging Cohort Study extend this signal to longitudinal echocardiographic outcomes: compared with veterans without HIV, veterans with HIV had higher incident PH risk, particularly when CD4 count was < 500 cells/µL or HIV RNA was ≥ 500 copies/mL [22]. Overall, the available evidence supports a combined risk model in which uncontrolled HIV replication or immunodeficiency may increase susceptibility, while sex, cardiometabolic risk, chronic viral hepatitis, smoking, and other co‐exposures modify the observed phenotype. Sub‐Saharan Africa: The “Missing Denominator” Problem The epidemiologic uncertainty is greatest where the HIV burden is highest. WHO regional estimates indicate that the WHO African Region had approximately 26.3 million people living with HIV in 2024, within a global population of approximately 40.8 million people living with HIV [1, 23]. To provide quantitative context, Figure 1 displays the WHO regional distribution of people living with HIV in 2024 and an illustrative HIV‐PAH case projection calculated by applying the 0.46% catheter‐confirmed French prevalence benchmark to regional PLWH counts [1, 15]. This arithmetic projection yields approximately 188,000 possible HIV‐PAH cases globally and approximately 121,000 in the WHO African Region. These values are not measured regional prevalence estimates; they are an illustrative contextual frame showing why even a rare complication becomes programmatically important when applied to tens of millions of PLWH. Despite this concentration of potential risk, the true population prevalence of right heart catheterization–confirmed HIV‐PAH is not established in most African countries, largely because systematic catheter‐based phenotyping remains scarce and most available data are derived from echocardiography in selected clinical populations. Global HIV burden and contextual projected HIV‑PAH case numbers. Horizontal bars show WHO regional estimates of people living with HIV (PLWH) in 2024, expressed in millions. Bar‐end labels provide the regional PLWH estimate and an illustrative projected number of HIV‐associated pulmonary arterial hypertension (HIV‐PAH) cases, calculated by applying the 0.46% catheter‐confirmed HIV‐PAH prevalence reported in the French screening study to each regional PLWH estimate. These projected counts are intended for epidemiologic context only and should not be interpreted as measured regional HIV‐PAH prevalence, because age structure, antiretroviral therapy access, HIV control, regional co‐factors, competing pulmonary hypertension etiologies, and access to right heart catheterization differ substantially across settings. HIV‐PAH, HIV‐associated pulmonary arterial hypertension; PLWH, people living with HIV. The scale and limitations of current African evidence are illustrated by the systematic review and meta‐analysis by Bigna and colleagues [14]. In that analysis, only three eligible African studies were identified (from South Africa, Tanzania, and Cameroon), all enrolling adults selected for cardiovascular symptoms and diagnosing pulmonary hypertension using echocardiographic pulmonary artery systolic pressure thresholds (PASP ≥ 35 mmHg). Across the pooled sample of 664 symptomatic patients, the prevalence of echocardiography‐defined pulmonary hypertension was 14% (95% CI 6–23%), with substantial between‐study variation (Tanzania 12.7%; Cameroon 29.5%; South Africa 8.1%) [14]. These figures are clinically important, but they should not be interpreted as “HIV‐PAH prevalence.” Rather, they indicate a clinically important burden of echocardiography‐defined PH among symptomatic people living with HIV, while also highlighting the high probability of phenotypic confounding. PAPUCO provides an important empirical illustration of this etiologic heterogeneity in sub‐Saharan Africa. In the HIV‐positive PH cohort, PH was defined using an echocardiographic right ventricular systolic pressure threshold > 35 mmHg, together with compatible symptoms and supportive electrocardiographic or chest radiographic findings, and cases were then classified according to the most likely WHO PH group. Among HIV‐positive patients with PH, 36% were classified as Group 1 PAH, 36% as Group 2 PH due to left heart disease, and 19% as Group 3 PH due to lung disease and/or hypoxia; in the HIV‐positive Group 3 subgroup, PH was attributed to previous tuberculosis in all cases. Previous or concurrent tuberculosis was recorded in 29 of 47 HIV‐positive PH patients (62%). These data reinforce that, in African HIV cohorts, an elevated echocardiographic estimate of pulmonary pressure should be treated as a syndromic PH signal requiring etiologic phenotyping rather than as a synonym for catheter‐confirmed HIV‐PAH [21]. Echocardiographic pressure estimates do not, by themselves, distinguish pre‐capillary PAH from post‐capillary PH due to left heart disease, hypoxic PH due to chronic lung disease including post‐tuberculosis lung damage, or chronic thromboembolic disease. The updated World Symposium/ERS classification underscores why this distinction matters, because treatment and prognosis diverge substantially across PH group [13]. A cautious but compelling inference follows. In settings where additional conditions that can cause or modify pulmonary hypertension are prevalent—including schistosomiasis‐associated PAH and hemoglobinopathy‐associated pulmonary vascular disease within the recognized PH classification framework [13], alongside high‐burden infections that impose repetitive inflammatory and endothelial stress such as malaria [24] —the overall burden of pulmonary hypertension among people living with HIV may exceed that observed in cohorts from high‐income settings [13]. Yet the fraction of this burden that represents true Group 1 HIV‐PAH, confirmed invasively and purified from alternative mechanisms, remains largely unquantified. This absence of a catheter‐confirmed denominator is not simply an academic gap; it is the reason epidemiology, diagnosis, and implementation strategy must be developed together, and it anticipates the clinical‐phenotype section that follows: when population prevalence is uncertain and etiologies overlap, earlier recognition depends on disciplined clinical suspicion and careful phenotyping rather than on symptoms alone [14]. Figure 2 summarizes the ascertainment cascade that generates the ‘missing denominator’ of catheter‐confirmed HIV‐PAH in many sub‐Saharan African settings. Ascertainment cascade and the “missing denominator” in HIV‐PAH epidemiology. Schematic comparison of typical case‐ascertainment pathways in high‐income settings versus sub‐Saharan Africa. In high‐income settings, screening (often echocardiography‐based) more frequently progresses to right heart catheterization (RHC), enabling estimation of RHC‐confirmed HIV‐PAH prevalence. In many low‐resource settings, limited access to echocardiography and particularly to RHC results in substantial attrition before invasive phenotyping, producing uncertainty in the true population prevalence of HIV‐PAH. HIV‐PAH, HIV‐associated pulmonary arterial hypertension; PH, pulmonary hypertension; RHC, right heart catheterization. Clinical Phenotype: The “Diagnostic Mimicry” and a Right Ventricle–First Disease HIV‐associated pulmonary arterial hypertension (HIV‐PAH) typically declares itself through progressive exertional dyspnea, early fatigue, and declining exercise tolerance, with more advanced disease marked by exertional presyncope or syncope, chest discomfort, and peripheral edema. Physical examination may reveal a loud pulmonic component of the second heart sound, a right ventricular (RV) heave, a tricuspid regurgitation murmur, hepatomegaly, ascites, or dependent edema; however, these classic signs are often absent until late in the course. This clinical evolution mirrors other forms of pulmonary arterial hypertension and is reflected in contemporary pulmonary hypertension guidance [25] and focused reviews of HIV‐associated disease biology and presentation [4]. The diagnostic challenge is amplified in settings where competing causes of dyspnea are common and frequently co‐exist within the same patient. In many low‐ and middle‐income countries, symptoms attributable to pulmonary vascular disease overlap substantially with tuberculosis and post‐tuberculosis lung disease, recurrent lower respiratory tract infection, bronchiectasis, anemia, and left‐sided heart disease. Post‐tuberculosis lung disease in particular has emerged as a major, under‐recognized contributor to chronic respiratory morbidity in high‐burden regions, creating a pervasive background of hypoxia and parenchymal damage that can generate pulmonary hypertension outside the PAH category [8]. The magnitude of this diagnostic confounder has recently been quantified more precisely. In a 2024 systematic review and meta‐analysis of tuberculosis‐associated PH, pooled PH prevalence among post‐TB populations varied substantially by clinical context: 67.0% in patients with chronic respiratory failure, 42.4% in hospitalized or symptomatic patients, and 6.3% in non‐healthcare‐seeking outpatients. Among patients with active tuberculosis, the pooled prevalence of PH was 9.4%. These estimates should be interpreted according to sampling frame: post‐TB PH is most enriched in symptomatic and respiratory‐failure cohorts, but even outpatient estimates provide a biologically plausible background against which HIV‐associated dyspnea and echocardiography‐defined PH may be misclassified without phenotype‐correct evaluation [8]. In parallel, heart failure and structural heart disease are increasingly documented in people living with HIV, including in sub‐Saharan Africa, further complicating the interpretation of elevated pulmonary pressures detected on echocardiography [11]. These realities help explain why echocardiography‐based studies in African HIV cohorts report substantial rates of “pulmonary hypertension” using estimated pressures, while right heart catheterization–confirmed HIV‐PAH remains poorly quantified at the population level [14]. Prognostically, HIV‐PAH is best understood as a disease in which the right ventricle is both the primary victim and the principal determinant of survival. In one of the classic series, pulmonary arterial hypertension was the direct cause of death in the majority of cases, underscoring that once RV failure is established, the terminal pathway is often cardiopulmonary collapse rather than opportunistic infection [26]. In the modern era, outcomes have improved with broader access to antiretroviral therapy and PAH‐targeted treatments, yet prognosis remains closely tied to cardiac function and immune status, reinforcing the centrality of RV preservation and early disease recognition [27]. Modern‐era survival data from high‐income settings provide useful benchmarks, while underscoring the same RV‐centered prognostic logic. In the French cohort reported by Degano and colleagues, overall survival in HIV‐PAH was 88% at 1 year and 72% at 3 years, with cardiac index and CD4 count associated with prognosis [27]. More recent Spanish REHAP registry data reported survival after HIV‐PAH diagnosis of 93.6%, 81.8%, and 74.0% at 1, 3, and 5 years, respectively [28]. Data from resource‐limited settings remain less mature. In PAPUCO, HIV‐positive patients with PH had substantial mortality during follow‐up, and the subgroup classified as HIV‐PAH appeared to have poorer survival than patients classified as having PH due to left heart disease or lung disease; however, interpretation is constrained by echocardiography‐based classification, incomplete invasive confirmation, and limited cause‐of‐death granularity [21]. Collectively, these observations reinforce that outcomes in HIV‐PAH are determined less by pulmonary pressure alone than by preservation or loss of RV reserve. The RV‐centered clinical trajectory of HIV‐PAH, including the narrowing therapeutic window before decompensation, is depicted in Figure 3. These observations motivate a clinical strategy that is not “pressure‐centric” but RV‐centric: the goal is to identify disease before adaptive RV remodeling gives way to irreversible decompensation, a principle that naturally transitions from phenotype to mechanism. Clinical trajectory in HIV‐PAH emphasizes a right ventricle–first prognosis. Conceptual depiction of rising pulmonary vascular load (PVR surrogate) over time and the delayed decline in right ventricular reserve. This figure is a conceptual schematic and is not derived from individual patient‐level longitudinal measurements. Symptoms may begin early (dyspnea, reduced exercise tolerance), while prognosis shifts sharply once RV reserve is exhausted and overt RV failure develops. The “therapeutic window” is the interval in which disease recognition and treatment may still preserve RV function. Pathobiology: HIV‐PAH as a Multi‐Hit Pulmonary Vasculopathy The current mechanistic view of HIV‐PAH is that it arises from convergent insults to the pulmonary vascular unit rather than from a single dominant trigger. The most coherent model integrates viral protein–mediated endothelial perturbation, chronic immune activation, dysregulated vasoactive signaling, oxidative stress and redox failure, and proliferative remodeling driven by growth‐factor and metabolic pathways, with clinical expression shaped by co‐exposures such as endemic infections and substance use. This “multi‐hit” framework is consistent with contemporary syntheses of HIV‐associated pulmonary vascular disease [4] and helps reconcile an epidemiologic paradox: HIV‐PAH persists in the antiretroviral therapy era despite profound reductions in systemic viremia, and screening studies continue to identify incident cases in treated populations [15]. A key element of persistence is compartmentalization of HIV biology within the lung. Multiple lines of evidence support the lung as a distinct immunologic and virologic niche, with ongoing immune dysregulation and signals consistent with reservoir dynamics even in individuals receiving suppressive antiretroviral therapy [29]. A focused review on pulmonary HIV reservoirs similarly emphasizes factors that influence viral burden and persistence within lung compartments [30]. In a multi‐hit model, such compartmentalization plausibly sustains endothelial activation and inflammatory signaling within the pulmonary circulation, thereby lowering the threshold for vascular remodeling when additional insults accumulate. Importantly, most evidence favors indirect vascular injury rather than productive infection of pulmonary endothelial cells as a prerequisite for HIV‐PAH. Experimental work has shown that human lung microvascular endothelial cells do not express typical HIV coreceptors on their surface in a manner consistent with robust direct infection, and that endothelial injury can instead be driven by HIV proteins and inflammatory mediators [31]. Among viral proteins, gp120 has been linked to pulmonary endothelial apoptosis and increased secretion of endothelin‐1, a potent vasoconstrictor and pro‐remodeling mediator central to PAH biology [32]. Translationally, endothelin‐1 has also been associated with hemodynamically confirmed HIV‐PAH, strengthening the plausibility of endothelin axis dysregulation as a clinically relevant pathway in this condition [33]. Nef represents another mechanistically compelling candidate. In an SHIV‐nef macaque model and in human tissues, Nef has been associated with complex pulmonary vascular lesions resembling the plexiform pathology of PAH, supporting a role for pleiotropic viral protein effects in vascular remodeling [34]. These data do not imply that viral proteins alone are sufficient in every patient; rather, they provide a biologically credible “hit” that may synergize with inflammation, co‐infection, and host susceptibility. Oxidative stress is widely recognized as a convergence node in pulmonary vascular remodeling, and HIV‐PAH offers specific examples of how viral proteins may destabilize redox homeostasis. In pulmonary arterial endothelial cells, Tat has been shown to repress Nrf2/ARE‐regulated antioxidant programs, thereby weakening cellular defenses against oxidative injury and potentially facilitating endothelial dysfunction and pro‐proliferative signaling [35]. Broader pulmonary hypertension biology also implicates reactive oxygen species derived from NADPH oxidases in vascular remodeling and smooth muscle proliferation, providing a mechanistic “landing zone” through which HIV‐related redox perturbations may translate into structural disease [36]. Consistent with this directionality, HIV‐protein expression in animal models alters pulmonary vascular resistance and can exacerbate susceptibility to pulmonary hypertensive phenotypes, offering experimentally tractable platforms for pathway dissection [37]. A clinically urgent second‐hit axis involves opioids and other substances that intersect with HIV epidemics through both structural vulnerability and biological synergy. Experimental studies demonstrate that combined exposure to morphine and viral proteins can induce autophagy in pulmonary endothelial cells, shifting the balance toward apoptosis resistance and proliferative remodeling and suggesting a mechanism for more severe vasculopathy in co‐exposed individuals [38]. These findings are not merely mechanistic curiosities; they highlight how social and pharmacologic realities can become molecular accelerants of pulmonary vascular disease. The multi‐hit framework may be particularly important in tropical settings, where endemic co‐infections can introduce repeated inflammatory and endothelial insults. Schistosomiasis is a recognized cause of group 1 PAH and is explicitly embedded in international clinical classification [13]. Malaria remains highly prevalent in the same geographic regions that bear a large HIV burden; WHO estimates indicate 282 million malaria cases and 610,000 malaria deaths globally in 2024, with the African Region carrying the vast majority of the burden [24]. In high‐income settings, chronic viral hepatitis—particularly hepatitis C virus (HCV) infection in older HIV cohorts and in populations with overlapping injection‐drug or other historical risk exposures—also deserves explicit attention [39]. In a Spanish echocardiographic cohort of people with HIV, chronic HCV infection was independently associated with elevated pulmonary pressures [19], and a later global synthesis identified HCV infection among recurrent risk variables reported across studies of PH in people living with HIV [14]. This association should be interpreted cautiously: HCV may act as a marker of shared exposures, but it may also contribute through chronic inflammation, hepatic fibrosis, and portal hypertension. Because portopulmonary hypertension is a recognized PAH phenotype in contemporary PH classification frameworks, suspected HIV‐PAH in Western cohorts should be evaluated alongside chronic liver disease and portal hypertension/portopulmonary hypertension [12, 13, 40]. Collectively, these tropical and non‐tropical co‐factors broaden the multi‐hit framework beyond HIV alone. While definitive catheter‐confirmed interaction data linking schistosomiasis, malaria, chronic viral hepatitis, and related co‐exposures to HIV‐PAH incidence are limited, the biological plausibility of additive endothelial activation, hemolysis‐driven nitric oxide dysregulation, portal‐hypertension‐associated pulmonary vascular disease, and chronic inflammatory priming is strong enough to justify focused epidemiologic and mechanistic studies in endemic and high‐risk populations, rather than uncritical extrapolation from cohorts in which the co‐factor ecology differs substantially. Within this mechanistic landscape, natriuretic peptide clearance receptor (NPR‐C) signaling and its regulation by PPARγ represent a plausible protective axis with translational relevance. Experimental work demonstrates that deletion of NPR‐C can produce pulmonary arterial hypertension phenotypes in vivo [41, 42, 43, 44, 45, 46, 47], and a comprehensive synthesis has proposed NPR‐C dysfunction as a paradigm for pathological remodeling and potential therapeutic targeting [41, 42, 43, 44, 45, 46, 47]. In parallel, PPARγ activation has been shown to attenuate hypoxia‐induced pulmonary hypertension and vascular remodeling in preclinical models, partly through suppression of oxidative and proliferative signals [48]. A parsimonious, testable translation hypothesis emerges: if HIV proteins and endemic co‐factors converge on oxidative stress and growth‐factor signaling, then restoring counter‐regulatory pathways such as NPR‐C/PPARγ may blunt remodeling and preserve RV–pulmonary vascular coupling. Mechanism‐informed hypotheses of this kind create a natural bridge to diagnostic strategy: when biology is multi‐hit and phenotypes are heterogeneous, precise classification becomes the prerequisite for rational treatment. Figure 4 presents an integrative multi‐hit model linking HIV‐related and regionally prevalent co‐factors to pulmonary vascular remodeling and RV afterload. HIV‐PAH as a multi‐hit pulmonary vasculopathy. Integrative model illustrating convergent drivers of pulmonary vascular remodeling and increased pulmonary vascular resistance, including HIV proteins (Tat, Nef, gp120), chronic immune activation, pulmonary compartmentalization/reservoir‐related signaling despite ART, oxidative stress/redox failure, substance exposure, endemic co‐factors (e.g., schistosomiasis, malaria, hepatitis co‐infection), and host susceptibility. These mechanisms interact through endothelial dysfunction, altered vasoactive signaling, growth‐factor/metabolic pathways, and vascular cell proliferation, culminating in increased RV afterload. Diagnosis: A Practical, Stepwise Strategy—Especially for Low‐Resource Settings Because symptoms are non‐specific and late findings are common, the highest‐yield diagnostic intervention is systematic clinical suspicion. In a person living with HIV, progressive exertional dyspnea, exertional syncope or presyncope, disproportionate fatigue, or signs of RV strain should trigger evaluation for pulmonary hypertension alongside more common causes of breathlessness. Transthoracic echocardiography remains the indispensable first‐line tool: it estimates pulmonary pressures, evaluates RV size and systolic function, quantifies tricuspid regurgitation velocity, and identifies features suggesting advanced disease such as right atrial enlargement or pericardial effusion. Yet echocardiography is a detection and triage instrument, not a definitive test for PAH. Contemporary guidance emphasizes that pulmonary arterial hypertension requires invasive hemodynamic confirmation and structured exclusion of alternative PH mechanisms [12]. A minimum‐to‐advanced, stepwise evaluation pathway for suspected HIV‐PAH is provided in Table 3. Table 3Stepwise evaluation for suspected HIV‑PAH in resource‐limited settings (minimum‐to‐advanced pathway).StepPurposeMinimum componentsEscalation/referral triggers1. Identify candidatesRaise pre‐test probabilityUnexplained exertional dyspnea, syncope/presyncope, edema, loud P2, RV heave; persistent symptoms after treatment of common infectionsRecurrent syncope, resting hypoxemia, signs of RV failure, rapid progression2. Basic assessmentExclude high‐frequency mimics and quantify severityHistory (TB, schistosomiasis exposure, VTE risk, substance exposure); exam; ECG; chest radiograph; CBC/hemoglobin; oxygen saturation; ± BNP/NT‑proBNPAbnormal ECG suggesting RV strain; cardiomegaly; severe anemia; hypoxemia; elevated natriuretic peptides3. EchocardiographyEstimate PH probability and assess RV/LVTR velocity and PH probability; RV size/function; right atrial size; pericardial effusion; LV systolic/diastolic function and valve diseaseHigh PH probability with RV dysfunction; uncertainty between pre‐ vs post‐capillary phenotype4. Etiologic phenotypingClassify likely PH group before PAH therapyScreen for Group 2/3 causes (LV disease; lung disease/hypoxia); assess thromboembolism history; treat correctable contributors (hypoxia/anemia)Suspected CTEPH; severe parenchymal lung disease; dominant LV disease; mixed mechanisms5. Right heart catheterization (when feasible)Confirm hemodynamics and guide therapymPAP, PAWP, cardiac output, PVR; vasoreactivity testing when indicated per guidelineAll patients considered for PAH therapy; unexplained RV failure; discordant echocardiography and clinical findings6. Longitudinal monitoringTrack risk and responseWHO functional class; 6‐min walk distance; natriuretic peptides; RV function on echocardiography when availableWorsening symptoms, rising biomarkers, RV dilation/dysfunction, recurrent hospitalizationAbbreviations: BNP, B‐type natriuretic peptide; ECG, electrocardiogram; LV, left ventricle; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricle; TB, tuberculosis; TR, tricuspid regurgitation; VTE, venous thromboembolism.John Wiley & Sons, Ltd. Stepwise evaluation for suspected HIV‑PAH in resource‐limited settings (minimum‐to‐advanced pathway). Abbreviations: BNP, B‐type natriuretic peptide; ECG, electrocardiogram; LV, left ventricle; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricle; TB, tuberculosis; TR, tricuspid regurgitation; VTE, venous thromboembolism. This distinction is especially important in HIV because pulmonary hypertension frequently reflects mixed mechanisms. Echocardiography must therefore be paired with directed phenotyping for left heart disease, chronic lung disease or hypoxia (including post‐tuberculosis lung disease), thromboembolic disease, and systemic contributors such as severe anemia. The African literature illustrates why this discipline matters: echocardiography‐based studies identify substantial rates of elevated estimated pulmonary pressures, but heterogeneous thresholds and limited catheter confirmation make it impossible to equate these findings with HIV‐PAH prevalence [14]. In this context, right heart catheterization serves two functions: it confirms pulmonary hypertension using contemporary hemodynamic definitions, and it classifies the physiology as pre‐capillary or post‐capillary, thereby protecting patients from misdirected therapy [12]. Where catheterization capacity is scarce, the realistic health‐system response is not to lower diagnostic standards but to reorganize access. Regional referral pathways and catheterization “hubs” can concentrate expertise, improve safety, and standardize phenotyping, while echocardiography and basic laboratory testing remain decentralized. A pragmatic diagnostic and referral pathway applicable to resource‐limited settings is outlined in Figure 5. For follow‐up and risk assessment, simple functional measures such as WHO functional class and 6‐min walk distance, together with natriuretic peptides (BNP or NT‐proBNP), provide pragmatic, scalable surveillance consistent with international risk frameworks [12]. Resource‐appropriate pathway for suspected HIV‐PAH: detect, phenotype, confirm, and treat. Pragmatic flow diagram beginning with clinical suspicion in PLWH with unexplained dyspnea or RV strain, followed by basic assessment and echocardiography‐based triage. The pathway emphasizes structured exclusion of dominant Group 2/3 causes and referral for RHC when pre‐capillary PH is likely, enabling confirmation, classification, and risk stratification before PAH‐targeted therapy. BNP, B‐type natriuretic peptide; NT‐proBNP, N‐terminal proBNP; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PLWH, people living with HIV; RHC, right heart catheterization; RV, right ventricle. Treatment: What Is Evidence‐Based, What Is Pragmatic, and What Is Still Unknown Antiretroviral therapy (ART) is foundational for all people living with HIV and should be optimized in patients with HIV‐PAH, yet ART alone is not a reliable disease‐modifying therapy once pulmonary vascular remodeling is established. Data from the Swiss HIV Cohort suggest that ART is associated with improved hemodynamics and survival in HIV‐related PAH, supporting the principle that HIV control remains necessary for best outcomes [18]. At the same time, modern series indicate that ART may be insufficient to reverse hemodynamic disease in many patients, and prognosis remains strongly tied to cardiac function and immune status [27]. The practical implication is that effective management generally requires both optimized HIV therapy and PAH‐targeted therapy when true group 1 disease is confirmed. Although randomized trial data specific to HIV‐PAH remain limited, available studies and accumulated clinical experience consistently support benefit from PAH therapies when appropriately selected and monitored. Endothelin receptor antagonism is supported by the BREATHE‐4 study, in which bosentan improved functional and hemodynamic measures in HIV‐associated PAH without apparent deterioration of HIV control, albeit in a small, uncontrolled design [49]. Prostacyclin therapy has also demonstrated hemodynamic and functional benefit in severe HIV‐associated pulmonary hypertension, exemplified by intravenous epoprostenol experience in a small cohort [50]. Phosphodiesterase‐5 inhibition is widely used in PAH practice and has been applied in HIV‐PAH; however, drug–drug interactions are not a theoretical concern but a central prescribing constraint. Pharmacokinetic data illustrate that ritonavir‐boosted protease inhibitor regimens can markedly increase sildenafil exposure, necessitating careful dosing and monitoring strategies [51]. These interaction risks have outsized consequences in low‐ and middle‐income settings, where ART substitution options and laboratory monitoring may be constrained. In such contexts, clinical programs require explicit, protocolized approaches to interaction screening, dose adjustment, and toxicity surveillance rather than ad hoc prescribing. Therapeutic options, HIV‐PAH evidence status, and practical ART interaction considerations are summarized in Table 4. The table distinguishes therapies supported by direct HIV‐PAH clinical evidence from therapies used mainly by extrapolation from broader PAH populations. In HIV‐PAH, bosentan and intravenous epoprostenol have the clearest HIV‐specific clinical evidence [49, 50], whereas evidence for phosphodiesterase‐5 inhibitors, other endothelin receptor antagonists, riociguat, most non‐intravenous prostacyclin‐pathway agents, and sotatercept is limited, interaction‐sensitive, or largely extrapolated from non‐HIV PAH populations [12, 51, 52]. Routine anticoagulation is not recommended in HIV‐PAH unless another conventional indication is present, such as venous thromboembolism, atrial fibrillation, mechanical valve disease, or chronic thromboembolic pulmonary hypertension [53]. Calcium‐channel blocker therapy is also generally not recommended, because durable vasoreactive benefit is rare in HIV‐PAH and long‐term CCB response in non‐idiopathic PAH has been limited [53, 54]. Beyond single‐agent strategies, contemporary PAH care increasingly uses risk‐stratified combination therapy and structured escalation pathways. While HIV‐PAH–specific trial evidence is thinner, the physiologic rationale aligns with broader PAH treatment principles when pre‐capillary group 1 disease is confirmed and interactions are managed [12]. Table 4PAH‐targeted therapy in HIV‐PAH: evidence signals and ART interaction considerations.Therapy classRepresentative agentsHIV‐PAH evidence statusEvidence in HIV‐PAHKey ART interaction/safety considerationsMonitoring prioritiesEndothelin receptor antagonistsBosentan, ambrisentan, macitentanDirect HIV‐PAH evidence for bosentan; other ERAs mainly extrapolatedBosentan improved functional and hemodynamic measures in BREATHE‐4; evidence for ambrisentan and macitentan in HIV‐PAH is less direct.CYP‐mediated interactions vary by agent; review ART regimen before initiation; monitor hepatotoxicity.Liver enzymes, WHO functional class, 6MWD, edema/volume status.PDE‐5 inhibitorsSildenafil, tadalafilCommonly used; HIV‐PAH‐specific evidence limited and interaction‐sensitiveUsed in HIV‐PAH practice, but robust HIV‐specific randomized data are limited.Ritonavir‐ or cobicistat‐boosted ART can increase PDE‐5 inhibitor exposure; dose adjustment and careful monitoring required.Blood pressure, adverse effects, functional status, interaction review at every ART change.Prostacyclin pathway agentsIV epoprostenol; inhaled/SC/PO prostacyclin analogues; selexipagDirect HIV‐PAH evidence strongest for IV epoprostenol; other agents extrapolatedIV epoprostenol improved hemodynamics and functional status in severe HIV‐associated pulmonary hypertension.Infusion access, catheter infection risk, cost, availability, and adherence feasibility must be assessed.Catheter complications, RV failure, volume status, biomarkers, 6MWD.sGC stimulatorRiociguatUnclear/unexplored in HIV‐PAHNo robust HIV‐PAH‐specific trial evidence; evidence mainly from broader PAH/CTEPH populations.Contraindicated with PDE‐5 inhibitors; ensure CTEPH workup when relevant.Blood pressure, syncope, drug interactions, pregnancy precautions.Activin signaling inhibitionSotaterceptProven in broader PAH; HIV‐PAH underrepresented/unexploredSTELLAR showed benefit in adults with PAH on background therapy, but HIV‐PAH‐specific evidence is limited.Monitor hematologic effects and blood pressure; HIV‐specific interaction data remain limited.Hemoglobin, platelets, blood pressure, functional endpoints, adverse events.Routine anticoagulationWarfarin or DOACs, when otherwise indicatedUsually not recommended solely for HIV‐PAHNo established HIV‐PAH benefit; use only for another clear indication.Increased bleeding concern; ART‐drug interactions with some anticoagulants.Bleeding risk, renal/liver function, INR if warfarin, interaction review.Calcium‐channel blockersAmlodipine, diltiazem, nifedipineUsually not recommended in HIV‐PAHLong‐term vasoreactive response is rare in HIV‐PAH/non‐idiopathic PAH.Risk of hypotension; CYP interactions possible with boosted ART.Only consider after expert‐center vasoreactivity confirmation; monitor blood pressure and symptoms. Note: Evidence status refers specifically to HIV‐PAH, not to PAH overall. “Extrapolated” indicates evidence derived mainly from broader PAH populations without robust HIV‐PAH‐specific trial data. Anticoagulation and calcium‐channel blockers should not be used routinely for HIV‐PAH unless another indication exists or a rare expert‐confirmed vasoreactive phenotype is present.Abbreviations: 6MWD, 6‐min walk distance; ART, antiretroviral therapy; CTEPH, chronic thromboembolic pulmonary hypertension; CYP, cytochrome P450; DOAC, direct oral anticoagulant; ERA, endothelin receptor antagonist; INR, international normalized ratio; PAH, pulmonary arterial hypertension; PDE‐5, phosphodiesterase type 5; PH, pulmonary hypertension; PLWH, people living with HIV; RV, right ventricle; sGC, soluble guanylate cyclase; WHO, World Health Organization.John Wiley & Sons, Ltd. PAH‐targeted therapy in HIV‐PAH: evidence signals and ART interaction considerations. Note: Evidence status refers specifically to HIV‐PAH, not to PAH overall. “Extrapolated” indicates evidence derived mainly from broader PAH populations without robust HIV‐PAH‐specific trial data. Anticoagulation and calcium‐channel blockers should not be used routinely for HIV‐PAH unless another indication exists or a rare expert‐confirmed vasoreactive phenotype is present. Abbreviations: 6MWD, 6‐min walk distance; ART, antiretroviral therapy; CTEPH, chronic thromboembolic pulmonary hypertension; CYP, cytochrome P450; DOAC, direct oral anticoagulant; ERA, endothelin receptor antagonist; INR, international normalized ratio; PAH, pulmonary arterial hypertension; PDE‐5, phosphodiesterase type 5; PH, pulmonary hypertension; PLWH, people living with HIV; RV, right ventricle; sGC, soluble guanylate cyclase; WHO, World Health Organization. A major recent advance in PAH therapeutics is targeting the activin signaling pathway. In the STELLAR phase 3 trial, sotatercept added to background therapy improved exercise capacity and multiple clinically relevant endpoints in adults with PAH [52]. Sotatercept subsequently received FDA approval for adults with PAH (WHO group 1), with prescribing information accessible through the FDA label [55]. HIV‐PAH patients have historically been under‐represented in large PAH trials, and the emergence of remodeling‐directed agents increases the urgency of inclusion strategies that allow HIV‐associated disease to be evaluated rather than assumed biologically equivalent. In the real world, especially where the PAH pharmacopeia is limited, pragmatism must be organized rather than improvised. Phenotype‐confirmation remains the first therapeutic act, because treating post‐capillary or hypoxic pulmonary hypertension as PAH can misfire. Optimizing ART, correcting anemia and hypoxemia when present, and managing RV congestion with judicious diuresis are universal. When PAH‐targeted therapy is feasible, selection should be guided by interaction profiles, monitoring capacity, and referral access, with longitudinal follow‐up anchored in functional status and natriuretic peptides in keeping with international risk frameworks [12]. Research Agenda: What Would Most Rapidly Change Practice The most immediate barrier to progress in HIV‐PAH is not conceptual but infrastructural: the absence of large, catheter‐confirmed cohorts in the regions where HIV burden and multi‐hit exposures are greatest. Epidemiologic studies must move beyond echocardiography‐only definitions toward structured screening with selective right heart catheterization and standardized phenotyping that distinguishes pulmonary arterial hypertension from the broader spectrum of pulmonary hypertension in people living with HIV [14]. Such cohorts should intentionally capture co‐exposures that are common in endemic regions—including schistosomiasis [4, 56] and malaria burden at the population level [24] —while also recording post‐tuberculosis lung disease and left heart disease phenotypes that frequently confound diagnosis [7, 29]. A parallel implementation‐science agenda should evaluate low‐cost detection technologies that can operate upstream of echocardiography or right heart catheterization referral. Standard 12‐lead ECG and chest radiography are already embedded in many district‐level clinical systems and may capture signals of right ventricular strain, right atrial enlargement, pulmonary vascular enlargement, parenchymal lung disease, or other PH‐compatible abnormalities. Recent studies suggest that deep‐learning ECG models can detect PH around the time of diagnosis and, in some cohorts, from ECGs obtained before clinical diagnosis [57, 58]. Emerging multimodal approaches that combine ECG and chest radiography may further improve triage performance and could be paired with pragmatic biomarkers such as BNP or NT‐proBNP where available [12, 59]. These tools should not be presented as substitutes for echocardiography or right heart catheterization, because PAH diagnosis and treatment selection still require phenotype‐correct evaluation and invasive confirmation when PAH‐specific therapy is being considered [12]. Their most appropriate role is as triage support: to prioritize people living with HIV who have disproportionate right ventricular strain or pulmonary vascular signals for echocardiography, referral, and phenotype‐confirming evaluation, particularly in settings where echocardiography‐based PH signals are common but catheter‐confirmed HIV‐PAH remains poorly quantified [14, 21]. Prospective validation in HIV, post‐tuberculosis, and African cohorts will be essential before implementation, with attention to local calibration, algorithmic bias, cost, interpretability, and integration into referral pathways. Mechanistic work should track the same realism. Multi‐hit experimental systems that combine HIV proteins with co‐factor exposures and that interrogate endothelial redox biology, autophagy control, and apoptosis resistance offer a direct path to identifying modifiable nodes. Existing mechanistic evidence already highlights tractable pathways—Tat‐mediated Nrf2 repression [35], Nef‐associated vascular lesion biology [60], gp120‐driven endothelin‐1 induction [31], and opioid–viral protein synergy through autophagy [38] —that can be expanded into intervention‐ready hypotheses. Finally, therapeutics research must emphasize inclusion rather than extrapolation. If sotatercept and other remodeling‐directed therapies reshape the PAH landscape [52], then HIV‐PAH cannot remain a perpetual subgroup too rare or “complex” to study; the global burden and regional risk context demand explicit enrollment strategies and interaction‐aware trial designs. Conclusion HIV‐associated pulmonary arterial hypertension remains under‐recognized, frequently misclassified, and too often diagnosed after the right ventricle has exhausted its compensatory reserve. In high‐income settings, prevalence estimates are reproducible but shaped by referral and ascertainment; in sub‐Saharan Africa and other high‐burden regions, the denominator of catheter‐confirmed disease is still missing, obscured by a dense background of post‐tuberculosis lung disease, left heart disease, endemic infections, and systemic comorbidities. Mechanistically, the most persuasive framework is multi‐hit pulmonary vasculopathy: viral proteins and persistent pulmonary immune dysregulation interact with oxidative stress, endothelin signaling, metabolic and growth‐factor pathways, and co‐exposures such as opioids and endemic infections. These realities make phenotype‐correct diagnosis the keystone of care and justify a pragmatic but rigorous approach that begins with suspicion and echocardiography and advances—where feasible—to right heart catheterization and structured exclusion of alternative pulmonary hypertension groups. The most immediate life‐saving intervention is earlier recognition and referral; the most decisive scientific step is building catheter‐confirmed cohorts and mechanistic programs that reflect the biology and co‐factor ecology of the regions where HIV is most prevalent. This table summarizes phenotype‐defining features that help differentiate HIV‐associated pulmonary arterial hypertension (HIV‐PAH; Group 1) from other common causes of pulmonary hypertension in people living with HIV, including left heart disease (Group 2), chronic lung disease/hypoxia and post‐tuberculosis lung disease (Group 3), chronic thromboembolic pulmonary hypertension (Group 4), and systemic/hematologic contributors (Group 5). The goal is to highlight clinical, echocardiographic, laboratory, and imaging signals that meaningfully alter diagnostic pathways, referral urgency for right heart catheterization, and the appropriateness of PAH‐targeted therapy. This table summarizes major historical, regional, and global studies that have shaped current estimates of HIV‐associated pulmonary arterial hypertension and HIV‐associated pulmonary hypertension. Studies are presented according to setting, population, diagnostic definition, key finding, and interpretive limitations. The table intentionally separates catheter‐confirmed PAH from echocardiography‐defined PH, because these approaches estimate different entities: right heart catheterization–confirmed cohorts approximate true pre‐capillary Group 1 HIV‐PAH, whereas echocardiographic cohorts detect a broader PH signal that may include left heart disease, chronic lung disease, post‐tuberculosis sequelae, hypoxic pulmonary vascular disease, and thromboembolic disease. This distinction is particularly important in resource‐limited settings, where access to right heart catheterization is limited and comorbid conditions that mimic or modify HIV‐PAH are common. Abbreviations: ART, antiretroviral therapy; HCV, hepatitis C virus; HIV‐PAH, HIV‐associated pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PASP, pulmonary artery systolic pressure; PH, pulmonary hypertension; PH‐LD, pulmonary hypertension due to lung disease and/or hypoxia; PH‐LHD, pulmonary hypertension due to left heart disease; PLWH, people living with HIV; RHC, right heart catheterization; RV, right ventricle; TB, tuberculosis; WHO, World Health Organization. This table provides a pragmatic, resource‐sensitive diagnostic sequence for evaluating people living with HIV (PLWH) with suspected pulmonary hypertension. The pathway begins with high‐yield bedside and basic investigations (history, examination, oxygen saturation, hemoglobin, ECG, chest radiograph) and progresses through echocardiography‐based triage to structured exclusion of dominant alternative etiologies, with referral for right heart catheterization where feasible to confirm pre‐capillary physiology and enable risk stratification before PAH‐specific treatment. This table summarizes major pulmonary arterial hypertension (PAH) therapeutic classes relevant to HIV‐associated PAH, distinguishing treatments with direct HIV‐PAH evidence from those supported mainly by extrapolation from broader PAH populations. Bosentan and intravenous epoprostenol have the clearest HIV‐PAH‐specific evidence, whereas evidence for other endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, non‐intravenous prostacyclin pathway agents, soluble guanylate cyclase stimulation, and activin‐signaling inhibition remains limited or largely extrapolated. The table also highlights key antiretroviral therapy interaction considerations, especially cytochrome P450–mediated interactions and the increased exposure risk associated with ritonavir‐ or cobicistat‐boosted regimens. Routine anticoagulation and calcium‐channel blocker therapy are not recommended solely for HIV‐PAH unless another clear indication exists or a rare expert‐confirmed vasoreactive phenotype is demonstrated. Author Contributions E.E.E. conceived the manuscript, developed the conceptual framework, and drafted the initial and final versions of the manuscript. M.A., I.D., N.I., M.C., L.A.A., M.M.F., M.M., and R.K. contributed to literature review, critical revision for intellectual content, and contextualization for resource‐limited settings. All authors reviewed, edited, and approved the final manuscript. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest.